Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 5/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.77 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.61 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7004947 | 0.92 | CYSLTR1 (0.85) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL9827537 | 0.91 | CYSLTR1 (0.83) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL26771312 | 0.91 | CYSLTR1 (0.82) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL28031105 | 0.89 | CYSLTR1 (0.80) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL7810130 | 0.88 | CYSLTR1 (0.79) | CYSLTR1GPBAR1CYSLTR2ALOX5AP | |
| SCHEMBL10545855 | 0.88 | CYSLTR1 (0.79) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL26771295 | 0.88 | CYSLTR1 (0.77) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL25213744 | 0.88 | CYSLTR1 (0.78) | CYSLTR1GPBAR1CYSLTR2ALOX5AP | |
| SCHEMBL10484526 | 0.88 | CYSLTR1 (0.81) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL26632675 | 0.88 | CYSLTR1 (0.78) | CYSLTR1GPBAR1CYSLTR2ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357159-A1 | QUINOLINE COMPOUNDS AS SELECTIVE AND/OR DUAL MODULATORS OF BILE ACID RECEPTORS AND LEUKOTRIENE CYSTEINYL RECEPTORS | PREC BIO THERAPEUTICS S R L (IT) | 2023-11-09 | — | — | US | disclosed |
| US-20230357159-A1 | QUINOLINE COMPOUNDS AS SELECTIVE AND/OR DUAL MODULATORS OF BILE ACID RECEPTORS AND LEUKOTRIENE CYSTEINYL RECEPTORS | PREC BIO THERAPEUTICS S R L (IT) | 2023-11-09 | — | — | US | disclosed |
| US-20230357159-A1 | QUINOLINE COMPOUNDS AS SELECTIVE AND/OR DUAL MODULATORS OF BILE ACID RECEPTORS AND LEUKOTRIENE CYSTEINYL RECEPTORS | PREC BIO THERAPEUTICS S R L (IT) | 2023-11-09 | — | — | US | disclosed |
| CN-116323560-A | Quinoline compounds as selective and/or dual modulators of bile acid receptors and leukotriene cysteinyl receptors | 精密生物治疗有限责任公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4192815-A1 | QUINOLINE COMPOUNDS AS SELECTIVE AND/OR DUAL MODULATORS OF BILE ACID RECEPTORS AND LEUKOTRIENE CYSTEINYL RECEPTORS | Precision Bio-Therapeutics S.r.l. (IT) | 2023-06-14 | — | — | EP | disclosed |
| CN-102491969-B | Heteroaromatic quinoline compounds and the purposes as PDE10 inhibitor thereof | PFIZER PRODUCTS INC. (US) | 2015-08-19 | — | — | CN | disclosed |
| US-5420131-A | Platelet activating factor antagonist or 5-lipoxygenase inhibitors | J. URIACH & CIA, S.A. (ES) | 1995-05-30 | — | — | US | disclosed |
| EP-0624588-A1 | New quinoline derivatives with pharmacological activity | J. URIACH & CIA. S.A. (ES) | 1994-11-17 | — | — | EP | disclosed |
| EP-0617032-A1 | Cyanomethylpyridine derivatives as PAF antagonists and 5-lipoxygenase inhibitors | J. URIACH & CIA. S.A. (ES) | 1994-09-28 | — | — | EP | disclosed |
| EP-0610943-A1 | Pyridinium derivatives useful as PAF antagonists | J. URIACH & CIA. S.A. (ES) | 1994-08-17 | — | — | EP | disclosed |
| US-5212182-A | Substituted quinolinyl- and naphthalenylbenzamides or benzylamines and related compounds useful as analgesics | AMERICAN HOME PRODUCTS CORPOORATION (US) | 1993-05-18 | — | — | US | disclosed |
| US-5082849-A | Antiinflammatory agents or antiallergens | AVENTIS PHARMACEUTICALS INC. | 1992-01-21 | — | — | US | disclosed |
| EP-0434827-A4 | QUINOLINYL-BENZOPYRAN DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D 4? | — | 1992-01-08 | — | — | EP | disclosed |
| WO-1991019475-A2 | QUINOLINYL-BENZOHETEROBICYCLIC DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D¿4? | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1991-12-26 | — | — | WO | disclosed |
| US-5041453-A | Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-08-20 | — | — | US | disclosed |
| EP-0434827-A1 | QUINOLINYL-BENZOPYRAN DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D 4? | RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1991-07-03 | — | — | EP | disclosed |
| WO-1991001123-A2 | QUINOLINYL-BENZOPYRAN DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D¿4? | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1991-02-07 | — | — | WO | disclosed |
| US-4977162-A | Quinolinyl-chromone derivatives and use for treatment of hypersensitive ailments | RORER PHARMACEUTICAL CORPORATION (US) | 1990-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357159-A1 | QUINOLINE COMPOUNDS AS SELECTIVE AND/OR DUAL MODULATORS OF BILE ACID RECEPTORS AND LEUKOTRIENE CYSTEINYL RECEPTORS | GPBAR1, CYSLTR1, CYSLTR2 | CYSLTR1 2/4885GPBAR1 1/4885CYSLTR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.